

Comprehensive genomic and tailored biomarker insights for optimal therapy selection in a single order

Cancer type	Add-on testing
Biliary/Cholangiocarcinoma	CLDN18.2, HER2 CDx, PD-L1 CDx (22C3)
Bladder	HER2, PD-L1 (22C3)
Breast	AR, ER, HER2 CDx, Ki-67, PD-L1 CDx (22C3), PR
Cervical	HER2, PD-L1 CDx (22C3)
Colorectal	HER2
Endometrial/Uterine carcinoma	ER, HER2, p53, PD-L1 (22C3), PR, PTEN
Esophageal adenocarcinoma (EAC)	CLDN18.2 CDx, HER2, PD-L1 CDx (22C3), PD-L1 CDx (28-8)
Esophageal squamous cell carcinoma (ESCC)	PD-L1 CDx (22C3)
Gastric/GEJ	CLDN18.2 CDx, HER2 CDx, PD-L1 CDx (22C3), PD-L1 CDx (28-8)
Head and neck squamous cell carcinoma (HNSCC)	HER2, PD-L1 CDx (22C3), HPV RNA ISH Panel
Hepatocellular carcinoma	HER2, PD-L1 (22C3)
Melanoma	PD-L1 (22C3)
Non-small cell lung cancer (NSCLC)*	ALK CDx, c-MET CDx, HER2, PD-L1 CDx (22C3), PD-L1 CDx (SP142), ROS1
Ovarian/Fallopian/Peritoneal	ER, FOLR1 CDx, HER2, PD-L1 CDx (22C3), PR, HRD [†] through NGS-based scoring
Pancreatic	CLDN18.2, HER2, PD-L1 (22C3)
Prostate	AR, HER2, PD-L1 (22C3), PTEN CDx
Renal/Renal Cell Carcinoma (RCC)	HER2, PD-L1 (22C3)
Sarcoma/GIST	HER2, PD-L1 (22C3)
Thyroid	HER2, PD-L1 (22C3)
Cancer of unknown primary (CUP)	AR, ER, HER2, PD-L1 (22C3), PR
Other	HER2, PD-L1 (22C3)

HER2 FISH reflex will occur for resulted 2+ equivocal IHC results.
If selected with order, PanTracer LBx will be added as a reflex if tissue testing is not possible or fails.

*PD-L1 CDx 28-8 and PD-L1 CDx SP263 are available to add to NSCLC cases by request.
[†]HRD scoring is validated for primary epithelial ovarian tumors only and is not available to New York State clients.

CDx = companion diagnostic; FISH = fluorescence in situ hybridization; GEJ = gastroesophageal junction; GIST = gastrointestinal stromal tumor; HPV = human papillomavirus; HRD = homologous recombination deficiency; IHC = immunohistochemistry; ISH = in situ hybridization; NGS = next-generation sequencing

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England. ©2026 NeoGenomics Laboratories, Inc. All rights reserved.